Femasys (NASDAQ:FEMY) Releases Earnings Results, Misses Estimates By $0.04 EPS

Femasys (NASDAQ:FEMYGet Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04), Zacks reports. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 120.13%. The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million.

Femasys Stock Performance

NASDAQ:FEMY opened at $1.03 on Thursday. Femasys has a 12 month low of $0.73 and a 12 month high of $2.40. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $22.90 million, a price-to-earnings ratio of -1.27 and a beta of -2.83. The firm has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.15.

Analyst Upgrades and Downgrades

FEMY has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Femasys in a report on Tuesday. Chardan Capital decreased their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday.

Get Our Latest Stock Report on FEMY

Femasys Company Profile

(Get Free Report)

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

See Also

Earnings History for Femasys (NASDAQ:FEMY)

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.